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Peripheral T cell lymphomas (PTCLs) belong   
to the category of the most aggressive non-
Hodgkin’s lymphomas with a high mortality rate, 
minimal  effectiveness  of  conventional  chemo-
therapy, and only 10–30% long-term survivors 
(Savage, 2007). PTCLU (PTCL unspecified) 
represents the largest PTCL subtype, and most 
patients present with advanced disease and fre-
quent involvement of extranodal sites including 
spleen, bone marrow, liver, or blood. Patho-
logically, there is usually a diffuse infiltrate of 
atypical large T cells that exhibit an activated phe-
notype and a gene expression signature that 
resembles that of activated T cells (Piccaluga et al., 
2007). Although PTCLs have a worse prognosis 
than aggressive B cell lymphomas, they are still 
largely treated the same way because rational 
treatment strategies for PTCL are currently miss-
ing (Escalón et al., 2005). The development 
of such strategies requires a better understand-
ing of the molecular PTCL pathogenesis and, 
in addition, preclinical animal models for the 
human disease.
The  chromosomal  translocation  t(5;9) 
(q33;q22) was recently identified as a recurrent 
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Peripheral T cell lymphomas (PTCLs) are highly aggressive malignancies with poor prognosis.  
Their molecular pathogenesis is not well understood and small animal models for the disease are 
lacking. Recently, the chromosomal translocation t(5;9)(q33;q22) generating the interleukin-2 
(IL-2)–inducible T cell kinase (ITK)–spleen tyrosine kinase (SYK) fusion tyrosine kinase was 
identified as a recurrent event in PTCL. We show that ITK-SYK associates constitutively with  
lipid rafts in T cells and triggers antigen-independent phosphorylation of T cell receptor (TCR)–
proximal proteins. These events lead to activation of downstream pathways and acute cellular 
outcomes that correspond to regular TCR ligation, including up-regulation of CD69 or production 
of IL-2 in vitro or deletion of thymocytes and activation of peripheral T cells in vivo. Ultimately, 
conditional expression of patient-derived ITK-SYK in mice induces highly malignant PTCLs with 
100% penetrance that resemble the human disease. Our work demonstrates that constitutively 
enforced antigen receptor signaling can, in principle, act as a powerful oncogenic driver. More-
over, we establish a robust clinically relevant and genetically tractable model of human PTCL.
© 2010 Pechloff et al.  This article is distributed under the terms of an Attribu-
tion–Noncommercial–Share Alike–No Mirror Sites license for the first six months 
after the publication date (see http://www.rupress.org/terms). After six months it 
is available under a Creative Commons License (Attribution–Noncommercial–Share 
Alike 3.0 Unported license, as described at http://creativecommons.org/licenses/
by-nc-sa/3.0/).
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Figure 1.  ITK-SYK mimics a TCR signal in vitro. (A) Schematic representations of ITK, SYK, and ITK-SYK. Kinase, tyrosine kinase domain. See text for  
details. (B) Constitutive ITK-SYK signaling in T cell lipid rafts. Jurkat cells were infected with retroviruses carrying ITK-SYK, ITK-SYKKD, ITK-SYKPHmut together with 
GFP (ITK-SYK, ITK-SYKKD, or ITK-SYKPHmut), or GFP only as a control (GFP). Lipid raft fractions from unstimulated or anti-CD3– (5 µg/ml) and anti-CD28  
(1 µg/ml)–stimulated cells were prepared and subjected to Western blot analysis with antibodies against ITK (top), phospho-tyrosine (p-Tyr), or phosphorylated JEM VOL. 207, May 10, 2010 
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PLC1 (p-PLC1). Dot blots with the lipid raft marker GM1 confirm equal loading. Data shown are representative of at least two independent experiments.  
(C) Phosflow analysis of ITK-SYK signaling. Jurkat cells were infected with ITK-SYK together with GFP or GFP only expressing retrovirus and intracellularly stained 
with activation-specific anti-phospho antibodies directed against the indicated T cell signaling molecules. Signaling was analyzed within the infected viable 
GFP+ populations. Data shown are representative of four independent experiments. (D) ITK-SYK triggers kinase and PH domain–dependent T cell activation. 
Jurkat cells were infected as in B, left unstimulated, stimulated with 10 µg/ml anti-CD3 and 2 µg/ml anti-CD28, or treated with 2 µM R406 as indicated and 
analyzed by FACS. The percentage of infected GFP+ CD69-expressing cells from unstimulated, stimulated, or R406-treated cells is indicated. Data shown are 
representative of five independent experiments. (E) ITK-SYK induces kinase and PH domain–dependent IL-2 production. Jurkat cells were infected as in B.  
Cells were left unstimulated, stimulated with 10 µg/ml anti-CD3 and 2 µg/ml anti-CD28, or treated with 2 µM R406 as indicated. IL-2 concentrations in the cell 
supernatants were determined by ELISA. Shown are the mean ± SD from triplicate samples. Data shown are representative of four independent experiments.
 
and specific genomic alteration in PTCLU (Streubel et al., 
2006). This translocation fuses the IL-2–inducible T cell kinase 
(ITK) and the spleen tyrosine kinase (SYK) genes. ITK and SYK 
are both required for normal antigen-induced lymphocyte ac-
tivation. ITK is the predominant TEC kinase family member 
expressed in T cells (Berg et al., 2005). It possesses an amino-
terminal  pleckstrin  homology  (PH)  domain  for  plasma   
membrane recruitment, a TEC homology (TH) domain, Src 
homology (SH) 3 and SH2 domains for association with T cell 
adapter proteins, and a kinase domain for TCR downstream 
signaling (Fig. 1 A). SYK is highly expressed in B lymphocytes 
and myeloid cells, where it plays essential roles for immune cell 
activation (Sada et al., 2001). It is also expressed in developing 
thymocytes (Palacios and Weiss, 2007). SYK contains tandem 
SH2 domains for ligand-induced association with the BCR   
or other ITAM (immunoreceptor tyrosine-based activation   
motif)–containing immunoreceptors and a kinase domain for 
the phosphorylation of receptor-proximal molecules and sub-
sequent signal transduction (Fig. 1 A).
The translocation t(5;9)(q33;q22) fuses the PH and TH 
regions from ITK to the SYK kinase domain (Fig. 1 A; Streubel 
et al., 2006). However, the molecular and cellular conse-
quences of ITK-SYK expression in lymphocytes are un-
known. In this paper, we show that ITK-SYK is a catalytically 
active tyrosine kinase that constitutively engages the antigen 
receptor signaling machinery in T cells. Conditional expres-
sion of ITK-SYK in vivo induces highly aggressive T cell 
lymphomas with 100% penetrance and clinical and pathologi-
cal features of the human PTCL. This work demonstrates that 
constitutively enforced antigen receptor signaling can act as a 
strong oncogenic driver in lymphoma pathogenesis and estab-
lishes a clinically relevant mouse model of human PTCL.
RESULTS
ITK-SYK is a lipid raft–associated tyrosine kinase that 
mimics a TCR signal
To study the role of ITK-SYK in lymphomagenesis, we 
isolated an ITK-SYK fusion transcript from a human tumor 
specimen harboring the t(5;9)(q33;q22) translocation (Streubel 
et al., 2006) and generated retroviral expression vectors that 
coexpress different ITK-SYK versions together with a GFP. 
In vitro kinase assays revealed that patient-derived ITK-
SYK is an active tyrosine kinase (unpublished data). Ex-
change of lysine to arginine in the ATP binding pocket of 
the kinase domain (K262R; equivalent to K402R in wild-
type SYK) resulted in a catalytically inactive ITK-SYKKD 
(kinase defective) version (unpublished data). To investigate 
functional  roles  of  the  ITK-SYK  PH  domain,  we  also   
introduced a point mutation into its lipid binding pocket by 
exchanging arginine 29 to cysteine (R29C; ITK-SYKPHmut). 
This mutation corresponds to the previously characterized 
R29C  mutation  in  the  PH  domain  of  wild-type  ITK   
that interferes with ITK membrane recruitment (Bunnell 
et al., 2000).
First, we transduced ITK-SYK and its variants into Jur-
kat cells to study effects on T cell signal transduction (Abraham 
and Weiss, 2004; Fig. 1 B). As a control, we used Jurkat cells 
that  had  been  infected  with  a  retrovirus  expressing  only 
GPF. Western blotting with an ITK-specific antibody dem-
onstrated strong and constitutive expression of ITK-SYK 
and ITK-SYKKD in lipid rafts (Fig. 1 B). These are the sub-
cellular fractions containing the membrane microdomains 
where TCR signaling is initiated (Dykstra et al., 2003). In 
contrast, the ITK-SYKPHmut version does as expected not   
associate with lipid rafts, although it is expressed in the 
nonraft  fractions  at  a  similar  level  to  that  of  ITK-SYK   
or ITK-SYKKD.
In  ITK-SYK–expressing  cells,  we  detected  tyrosine 
phosphorylation of several lipid raft–associated proteins in-
cluding tyrosine phosphorylation of the TCR signal trans-
ducer PLC1 (Samelson, 2002). The pattern of tyrosine 
phosphorylation was similar to that of control Jurkat cells 
after stimulation with agonistic anti-CD3 and anti-CD28 
antibodies to trigger antigen receptor signaling. Moreover, 
we observed a recruitment of endogenous ITK into the 
lipid rafts of ITK-SYK–expressing T cells as well as into 
rafts of cells that were stimulated via their TCR and CD28. 
In contrast, Jurkat cells that were transduced with ITK-
SYKKD or ITK-SYKPHmut cells did not recruit ITK into 
lipid rafts and did not exhibit protein tyrosine phosphoryla-
tion above baseline. (Fig. 1 B).
Normal TCR signaling in Jurkat cells induces phosphory-
lation of the TCR-proximal adapters SLP-76 and LAT and sub-
sequent activation of several downstream pathways, leading to 
the up-regulation of the activation marker CD69 and pro-
duction of IL-2 (Samelson, 2002; Abraham and Weiss, 2004). 
To further study ITK-SYK signaling, we used intracellular 
flow cytometry with activation-specific antibodies directed 
against phosphorylated TCR signaling molecules (phosflow; 
Fig. 1 C). Constitutive ITK-SYK expression triggers tyro-
sine phosphorylation of SLP-76 and LAT. Again, PLC-1 
phosphorylation was also detected. Moreover, we observed 1034 New model of peripheral T cell lymphoma | Pechloff et al.
PH domain because ITK-SYKKD or ITK-SYKPHmut versions 
did not enhance CD69 expression.
ITK-SYK also triggered a profound production of IL-2, 
which was even higher than the IL-2 production induced by 
optimal CD3/CD28 costimulation with agonistic antibodies   
(Fig. 1 E). Similar to the up-regulation of CD69, the ITK-SYK–
induced secretion of IL-2 required an intact ITK-SYK kinase 
and PH domain.
To investigate the importance of ITK-SYK kinase activity 
in an alternative way, we also tested whether ITK-SYK signal-
ing might be sensitive to small molecule inhibition. To this end, 
we used the immunosuppressant wild-type SYK inhibitor R406 
constitutive activation of the AKT, ERK, and p38 MAP ki-
nase  downstream  pathways  in  ITK-SYK–expressing  cells. 
The protein phosphorylation pattern correlated to that of 
control cells that were acutely stimulated with CD3 and CD28 
antibodies (Fig. S1).
As cellular readouts for ITK-SYK function, we then moni-
tored CD69 expression and IL-2 production (Fig. 1, D and E). 
Strong up-regulation of CD69 was detected in ITK-SYK–
expressing cells, as well as in CD3/CD28-stimulated cells, 
but not in noninfected cells or cells infected with a GFP control 
virus (Fig. 1 D). The up-regulation of CD69 by ITK-SYK 
was dependent on both an intact kinase domain and an intact 
Figure 2.  A mouse model for conditional ITK-SYK expression. (A) Schematic representation of the gene-targeting strategy. A targeting vector that  
carries the human ITK-SYK cDNA together with an IRES eGFP sequence preceded by a loxP-flanked NEO-STOP cassette was constructed and used to generate  
Rosa26loxSTOPlox-ITK-SYK mice as described in Materials and methods. The recombinant Rosa26 locus and the ITK-SYK–expressing locus upon Cre-mediated deletion of 
the NEO-STOP cassette are indicated. SA, splice acceptor site; pA, polyA sequence; 1–3, Rosa26 exon 1–3; probe, flanking probe for Southern blot analysis.  
(B) Southern blot analysis. Genomic DNA from a wild-type (WT) and a successfully targeted Rosa26loxSTOPlox-ITK-SYK embryonic stem cell clone was digested with XbaI 
and Southern blotted with the flanking probe indicated in A. Sizes of the wild-type and recombinant (Rec) fragments are indicated. (C) Conditional expression of 
ITK-SYK in T and B cells in vivo. ROSA26loxSTOPlox-ITK-SYK mice were crossed to CD4-Cre or CD19-Cre transgenic mice for T or B cell–specific ITK-SYK expression.  
Peripheral lymphocyte suspensions of double transgenic 5-wk-old ITK-SYKCD4-Cre or ITK-SYKCD19-Cre mice were stained against TCR- or B220. eGFP fluorescence 
indicative of ITK-SYK expression in the TCR-+ T cells or B220+ B cells of the respective animals was analyzed using FACS. Data shown are representative of >40 mice  
per genotype analyzed. (D) Western blot analysis of conditional ITK-SYK expression. Individual mature T and B cell populations from 5-wk-old Rosa26loxSTOPlox-ITK-SYK, 
ITK-SYKCD4-Cre, and ITK-SYKCD19-Cre mice were sorted with magnetic beads and subjected to Western blot analysis with an anti-ITK antibody. Bands of wild-type ITK and 
ITK-SYK are indicated. Western blotting for -actin demonstrated equal protein loading. Data shown are representative of five independent experiments.JEM VOL. 207, May 10, 2010 
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Figure 3.  ITK-SYK mimics a TCR signal in vivo. 
(A) ITK-SYK expression in the thymus of ITK-SYKCD4-Cre 
animals. Thymocytes were stained against CD4 and 
CD8 and analyzed by FACS. eGFP fluorescence in-
dicative of ITK-SYK expression was measured in the 
CD4+CD8+ DP and in the CD4+ or CD8+ SP popula-
tions of 4–5-wk-old ITK-SYKCD4-Cre or control (CD4-
Cre transgenic) mice. (B and C) ITK-SYK induces DP 
thymocyte deletion. (B) Thymocytes were stained as 
in A and analyzed for the expression of CD4 or 
CD8. The frequencies of individual thymocyte sub-
sets are indicated. (C) The total DP or SP thymocyte 
cell numbers from ITK-SYKCD4-Cre (n = 9) or control 
(n = 6) mice are shown. (D) Total splenic B or T cell 
numbers from ITK-SYKCD4-Cre (n = 10) or control  
(n = 9) mice are indicated. Each symbol in C and D 
represents an individual mouse. Statistical signifi-
cance was analyzed using the unpaired two-tailed 
Student’s t test. ***, statistically significant (P < 
0.0001); ns, not statistically significant (P ≥ 0.05). 
Horizontal bars indicate the means. (E and F) Single 
cell suspensions from lymph node (LN) or spleen 
(SPL) from 4–5-wk-old ITK-SYKCD4-Cre or control 
mice were stained against CD4 and CD8. (E) CD4 
and CD8 expression was analyzed by FACS. The 
frequencies of individual T cell subsets are indi-
cated. (F) eGFP fluorescence indicative of ITK-SYK 
expression was determined in peripheral CD4+ or 
CD8+ T cells of ITK-SYKCD4-Cre or control mice. Data 
from spleen are shown. (G) ITK-SYK expressing  
T cells exhibit an activated phenotype in vivo.  
Peripheral lymphocytes from 4–5-wk-old ITK-
SYKCD4-Cre or control mice were stained against CD4, 
CD8, CD44, CD62L, and TCR-. Forward scattering 
(FCS) as a parameter for cell size and expression of 
CD44, CD62L, and TCR- was analyzed in the CD4+ 
and CD8+ T cell compartments using FACS. Data 
shown in A, B, and E–G are representative of five 
independent experiments with a total number of at 
least 10 mice analyzed per genotype. (H) ITK-SYK 
induces PLC1 phosphorylation in primary T cells in 
vivo. Splenic T cells were isolated from control or 
ITK-SYKCD4-Cre mice that were >12 wk old. Cells 
were left unstimulated and control cells addition-
ally stimulated with 5 µg/ml of anti-CD3 and  
1 µg/ml of anti-CD28. Lipid raft fractions were 
prepared and subjected to Western blot analysis 
with an anti–phospho-PLC1 antibody. Dot blots 
for GM1 show successful raft preparation and 
equal loading. Data shown are representative of 
three independent experiments. Black lines indicate 
that intervening lanes have been spliced out.1036 New model of peripheral T cell lymphoma | Pechloff et al.
Figure 4.  B cell–intrinsic ITK-SYK expression does not affect B cell development or activation. (A) Single cell suspensions from the spleens or peri-
toneal cavities of ITK-SYKCD19-Cre or control (CD19-Cre) mice were stained against B220, CD21, CD23, and CD5. eGFP fluorescence indicative of ITK-SYK expres-
sion was determined in the splenic follicular (FO), splenic marginal zone (MZ), or peritoneal B1 B cell compartments using FACS. (B) Cytoplasmic extracts of 
purified mature B cells from 5-wk-old control or ITK-SYKCD19-Cre mice were subjected to Western blot analysis with an antibody against phospho–tyrosine  
(p-Tyr). Western blotting for -actin demonstrated equal protein loading. Data shown are representative of three independent experiments. (C) Total splenic  
B or T cell numbers from ITK-SYKCD19-Cre (n = 12) or control (n = 6) mice are shown. Each symbol represents an individual mouse. Statistical significance was 
analyzed using the unpaired two-tailed Student’s t test. ns, non–statistically significant differences (P ≥ 0.05). Horizontal bars indicate the means. (D) Lym-
phocyte preparations from bone marrow (BM) or spleen (SPL) of ITK-SYKCD19-Cre or control mice were stained against B220, IgM, CD21, or CD23 and analyzed 
by FACS. The percentages of individual B cell populations are indicated. FO, follicular B cells; MZ, marginal zone B cells. (E) Forward scattering (FCS) and  
expression of CD86 was analyzed on B220+ mature B cells from ITK-SYKCD19-Cre or control mice using FACS. Data shown in A and C–E are representative of 
four independent experiments with total numbers of at least six 5–7-wk-old mice per genotype analyzed. (F) ITK-SYK is constitutively associated with T but 
not with B cell lipid rafts. Lipid raft and nonraft fractions were prepared from purified splenic T cells of control or ITK-SYKCD4-Cre mice or from mature B cells of 
ITK-SYKCD19-Cre mice that were >12 wk old. The fractions were subsequently analyzed for the presence of ITK or ITK-SYK by Western blot analysis using an 
antibody against ITK. Dot blots for GM1 show successful raft preparation and equal loading. Data shown are representative of three independent experiments.
which is currently in clinical trails for inflammatory, autoim-
mune, and selected malignant diseases (Weinblatt et al., 2008; 
Friedberg et al., 2010). Both ITK-SYK–induced up-regulation 
of CD69 and IL-2 production were completely blocked by 
R406 treatment (Fig. 1, D and E).
Together, these first in vitro experiments indicate that 
ITK-SYK is a lipid raft–associated tyrosine kinase, which con-
stitutively engages molecular components of the TCR sig-
naling machinery and thereby mimics aspects of a TCR signal 
in the absence of a ligand. Because an SYK kinase inhibitor 
or inactivating mutations in the ITK-SYK kinase or PH do-
main block ITK-SYK signaling, we additionally conclude 
that both kinase activity and membrane recruitment are es-
sential for productive ITK-SYK signal transduction.
A mouse model for conditional ITK-SYK expression
Based on the association of ITK-SYK with human PTCLs,   
we particularly wanted to study the effects of ITK-SYK sig-
naling in lymphocytes in vivo. To this end, we created a novel 
mouse model that allows ITK-SYK expression in a controlled 
and inducible fashion (Fig. 2). We introduced a human ITK-
SYK fusion cDNA preceded by a loxP-flanked transcrip-
tional and translational STOP cassette into the ubiquitously 
expressed Rosa26 locus using previously established gene 
targeting (Sasaki et al., 2006; Fig. 2, A and B). The resulting 
Rosa26loxSTOPlox-ITK-SYK mice were crossed to CD4-Cre trans-
genic animals (Lee et al., 2001) to induce T cell–specific excision 
of the STOP cassette and T cell–restricted ITK-SYK ex-
pression in the Rosa26loxSTOPlox-ITK-SYK × CD4-Cre double JEM VOL. 207, May 10, 2010 
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diminishment of the SP populations (Fig. 3 C) and reduced 
numbers (Fig. 3 D) and frequencies (Fig. 3 E) of mature pe-
ripheral T cells. Still, the majority of the peripheral CD4+ and 
CD8+ T cells express the fusion kinase (Fig. 3 F; Fig. 2, C and D; 
and not depicted). These ITK-SYK–expressing CD4+ and CD8+ 
peripheral T cells exhibit an activated phenotype, which is 
characterized by a large cell size, high expression of the activa-
tion marker CD44, and low expression of CD62L (Fig. 3 G). 
Furthermore, these cells show down-regulated TCR- sur-
face expression. Histological in vivo analysis revealed that these 
activated T cells are highly proliferative but do not undergo 
apoptosis, as determined by Ki-67 immunohistochemistry and 
staining for active Caspase-3 (Fig. S2). Moreover, ITK-SYK–
expressing T cells exhibit tyrosine phosphorylation of multiple 
lipid raft–associated proteins, including PLC-1, that is similar 
to wild-type T cells that are stimulated via the TCR with anti-
CD3/CD28 antibodies (Fig. 3 H and not depicted). B cell de-
velopment was not affected in ITK-SYKCD4-Cre mice (Fig. 3 D 
and not depicted).
To test whether B cell–intrinsic expression of ITK-SYK 
would influence B cell development or activation, we analyzed 
ITK-SYKCD19-Cre mice. In these animals, we observed an onset 
of B cell–specific ITK-SYK expression in the bone marrow and 
high percentages of ITK-SYK–expressing B cells in all periph-
eral B cell compartments including follicular, marginal zone, 
and B1 B cells (Fig. 4 A; Fig. 2, C and D; and not depicted). 
However, the overall protein tyrosine phosphorylation pattern 
did not differ between wild-type and ITK-SYK–expressing B 
lymphocytes (Fig. 4 B). Moreover, we did not detect any effects 
of B cell–intrinsic ITK-SYK expression on the total B cell 
transgenic offspring (from now on called ITK-SYKCD4-Cre 
mice). As Cre-catalyzed recombination also induces enhanced 
GFP (eGFP) expression from an internal ribosomal entry site 
(IRES), we can visualize ITK-SYK–expressing cells. To in-
duce ITK-SYK expression in the B cell lineage, we crossed 
the Rosa26loxSTOPlox-ITK-SYK line with CD19-Cre transgenic 
animals (Rickert et al., 1997; double-transgenic offspring called 
ITK-SYKCD19-Cre mice). FACS analysis in 5-wk-old animals 
revealed specific expression of the recombined ITK-SYK 
allele in >85% of peripheral T cells of ITK-SYKCD4-Cre mice 
or B cells in ITK-SYKCD19-Cre mice (Fig. 2 C). Expression of 
the ITK-SYK protein in the respective lymphocyte lineages 
was confirmed by Western blotting (Fig. 2 D).
ITK-SYK can imitate a TCR but not a BCR signal in vivo
We  first  focused  on  lymphocyte  development  in  young   
(4–5-wk-old) animals. The CD4-Cre transgene mediates loxP 
recombination at the CD4+CD8+ double-positive (DP) stage 
of thymocyte development and continues in single-positive 
(SP) cells (Lee et al., 2001). The DP stage is the period of T cell 
differentiation, when thymocytes expressing autoreactive 
TCRs receive strong TCR signals and are subsequently deleted 
by negative selection to prevent autoimmunity (Sebzda et al., 
1999). As expected, ITK-SYK expression was observed at the 
DP stage in ITK-SYKCD4-Cre mice (Fig. 3 A), leading to a pro-
found reduction in the frequencies and absolute numbers of 
DP thymocytes in these animals (Fig. 3, B and C). These find-
ings are consistent with the hypothesis that ITK-SYK imitates 
features of a strong TCR signal, as observed in our in vitro ex-
periments in Fig. 1. The decrease in DP cells is followed by a 
Figure 5.  Conditional expression of ITK-SYK in T cells induces a lymphoproliferative disease. (A) Peripheral blood samples from ITK-SYKCD4-Cre 
(starting with n = 19) and ITK-SYKCD19-Cre mice (n = 8) were obtained at the indicated time points. The frequencies of eGFP fluorescent lymphocytes in 
individual animals were determined by FACS analysis. The total number of ITK-SYKCD4-Cre mice declined over time as a result of disease-related mortality. 
Horizontal bars indicate the means. (B) Kaplan-Meier curve of ITK-SYKCD4-Cre (n = 73) and control (CD4-Cre) mice (n = 15). (C) Macroscopic appearance  
of representative spleens from 20-wk-old control and ITK-SYKCD4-Cre mice are shown (in centimeters). (D) Splenocytes from 20-wk-old control and  
ITK-SYKCD4-Cre mice were stained with antibodies against TCR-. The frequency of eGFP–expressing T cells in a diseased ITK-SYKCD4-Cre mouse is indicated. 
Data shown in C and D are representative of a total number of 20 mice per genotype analyzed.1038 New model of peripheral T cell lymphoma | Pechloff et al.
Figure 6.  PTCL in ITK-SYKCD4-Cre mice. (A) Disruption of the splenic architecture with highly proliferative cells in ITK-SYKCD4-Cre mice was revealed by 
hematoxylin and eosin (H&E) staining and immunohistochemistry with anti–Ki-67 antibodies. Bars: (black) 1 mm; (white) 50 µm. Data shown are repre-
sentative of five diseased ITK-SYKCD4-Cre mice analyzed. (B) Splenic cells from diseased ITK-SYKCD4-Cre mice were stained against CD4 and CD8 and analyzed 
by FACS. Selected examples of each type of T cell expansion from a total number of 40 mice analyzed are shown. (C) Bone marrow cell preparations from 
diseased ITK-SYKCD4-Cre or control (CD4-Cre) mice were stained with antibodies against TCR-. The frequency of eGFP+ T cells is indicated. Data are repre-
sentative of five independent experiments with a total number of 15 mice per genotype analyzed. (D) Solid organ infiltration of abnormal CD3+ T cells. 
Tissue sections from kidney (KID), liver (LIV), and lung (LNG) of affected ITK-SYKCD4-Cre animals were stained with H&E. Immunohistochemistry with anti-
CD3 antibodies was additionally performed. Bars: (black) 200 µm; (white), 1 mm. Data shown are representative of five diseased ITK-SYKCD4-Cre mice  JEM VOL. 207, May 10, 2010 
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numbers (Fig. 4 C), the frequencies of individual B cell sub-
sets (Fig. 4 D and not depicted), B cell size, or activation sta-
tus (Fig. 4 E and not depicted). Thus, although the TCR and 
BCR share many molecular features of downstream signaling 
(Myung et al., 2000), enforced B cell–specific expression of 
ITK-SYK has apparently no overt effects on B cell biology.
We hypothesized that the fundamentally different func-
tions of ITK-SYK in the T and B cell lineage could, in part, 
be the result of a cell type–specific localization of the fusion 
kinase into subcellular compartments because the protein re-
gion that is responsible for membrane recruitment originates 
from the T cell kinase ITK. Indeed, although T cells from 
ITK-SYKCD4-Cre mice and B cells from ITK-SYKCD19-Cre 
mice express similar amounts of ITK-SYK in cytoplasmic non-
raft fractions, the association of ITK-SYK with lipid rafts is 
only observed in T and not in B cells (Fig. 4 F). Similar to that 
seen in Fig. 1 B, ITK-SYK expression in T cells also induces 
recruitment  of  wild-type  ITK  into  lipid  rafts.  Thus,  the 
combined analysis of ITK-SYKCD4-Cre and ITK-SYKCD19-Cre 
mice demonstrates that ITK-SYK mimics a strong antigen 
receptor signal in primary T cells but not in B cells in vivo. 
The results additionally indicate that ITK-SYK depends   
on an appropriate cellular microenvironment for produc-
tive signaling.
ITK-SYK expression in T cells induces  
a lymphoproliferative disease
To investigate potential oncogenic roles of ITK-SYK, we were 
especially interested in the long-term consequences of ITK-
SYK expression in vivo. Therefore, we followed cohorts of 
ITK-SYKCD4-Cre (n = 19) and ITK-SYKCD19-Cre mice (n = 8) 
and  regularly  determined  the  frequencies  of  eGFP+  ITK-SYK– 
expressing T or B cells in their peripheral blood (Fig. 5 A). The 
percentages of ITK-SYK–expressing T cells increased continu-
ously in ITK-SYKCD4-Cre mice and rose up to almost 100%, in-
dicating a profound T cell lymphoproliferative disorder. Starting 
at 12 wk of age, the animals became overtly ill and eventually 
developed wasting and runting symptoms, lethargy, hunched 
postures, and distended abdomens. We had to sacrifice several 
mice from this series for ethical reasons. However, the medium 
frequency of ITK-SYK–expressing B cells in ITK-SYKCD19-Cre 
mice stayed constant during that time (Fig. 5 A).
Next, we obtained survival curves from ITK-SYKCD4-Cre 
(n = 73) and control mice (n = 15; Fig. 5 B). Although all ITK- 
SYKCD4-Cre animals succumbed to disease or had to be eutha-
nized within 27 wk of age, the control mice did not develop 
any pathological symptoms.
ITK-SYK–expressing mice develop PTCL
To characterize the disease in ITK-SYKCD4-Cre mice in detail,   
we sacrificed animals at 20 wk of age or upon disease signs. 
All spleens of ITK-SYKCD4-Cre mice were massively enlarged 
(Fig. 5 C) and consisted mainly of ITK-SYK–expressing 
TCR-+ and eGFP+ T cells with an activated phenotype 
(Fig. 5 D and not depicted; n = 40 mice analyzed). Histological 
analysis revealed a complete disruption of the normal spleen 
architecture by a diffuse infiltrate of medium- to large-sized 
lymphoid cells that exhibited irregular nuclei, prominent nu-
cleoli, and high mitotic rates strongly suggestive of a neoplastic 
growth (Fig. 6 A). Ki-67 staining further demonstrated a high 
proliferation (Fig. 6 A). The abnormal T cell populations were 
primarily CD4+ in 61% of the animals (Type I), predomi-
nantly CD8+ in 23% (Type II), and a mix of CD4+ and CD8+ 
T cells in the remaining mice (Type III; Fig. 6 B). The atypical 
lymphoid cells always infiltrated the bone marrow (Fig. 6 C) 
and grew invasively into solid organs, including kidneys, livers, 
and lungs (Fig. 6 D). Immunohistochemical analysis with anti-
CD3 antibodies confirmed the T cell nature of the infiltrate 
(Fig. 6 D). To characterize clonality, we analyzed their TCR-V 
chain repertoire by flow cytometry (Fig. 6 E). The repertoire 
was always skewed and consistently enriched for individual 
TCR-V clones (n = 33 mice analyzed). Although the specifi-
cally expanded TCR-V chain clones differed among distinct 
animals, we regularly observed that the identical T cell clones 
infiltrated all tested tissues in one individual mouse. To 
further study T cell clonality, we performed a PCR-based 
and computer-assisted fragment length analysis (Genescan) 
for TCR- and TCR- locus gene rearrangements (Kneba et al., 
1995; van Dongen et al., 2003). Clonal TCR rearrangements 
were detected in all tested diseased ITK-SYKCD4-Cre (n = 3)   
but not in CD4-Cre control mice (n = 4; Fig. 6 F and   
not depicted).
Finally,  we  tested  whether  ITK-SYK–induced  T  cell   
tumors could be transplanted. To this end, we injected ITK-
SYK–expressing T cells from affected animals intravenously 
into recipient mice. Tail blood analysis documented that the 
transplanted cells could massively expand in the recipients 
(Fig. 7 A). Morphological and flow cytometric analyses again 
revealed a lethal infiltration into lymphoid and nonlym-
phoid organs that was identical to the original disease (Fig. 7,   
B–D). Thus, enforced ITK-SYK expression in the T cell 
lineage induces a highly aggressive transplantable T cell lym-
phoma with a malignant growth pattern that resembles the 
clinical and pathological features of human PTCL (Cotta and   
Hsi, 2008).
analyzed. (E) Selective expansion of distinct T cell clones. Single cell suspensions from spleen (SPL), kidney (KID), and liver (LIV) of three individual mice 
were stained with antibodies against CD4, CD8, and a panel of TCR-V chain–specific antibodies (see Materials and methods). Frequencies of CD4+ or 
CD8+ cells expressing the indicated TCR-V chains in the spleen of control mice (open histograms) or frequencies of cells expressing the indicated TCR-V 
chains in spleen, kidney, and liver from diseased ITK-SYKCD4-Cre mice (gray histograms) are shown. (F) Genescan analysis for TCR gene rearrangements. 
Representative fragment size distributions of fluorochrome-labeled PCR products of the D2/J2 junction of a control and a diseased ITK-SYKCD4-Cre 
mouse are shown. Data shown are representative of three mice per genotype analyzed. Data in A–F are from ITK-SYKCD4-Cre mice that were older than  
12 wk and showed disease symptoms.
 1040 New model of peripheral T cell lymphoma | Pechloff et al.
DISCUSSION
Chromosomal  translocations  in  hematological  malignancies 
have always provided key insights into disease pathogenesis. 
Although some specific translocations are rare, the signaling path-
ways that are deregulated by these events are regularly hit by 
alternative genetic mechanisms such as mutations or amplifica-
tions in translocation negative cases or other tumor subentities 
(Fröhling and Döhner, 2008). As these aberrant signals directly 
trigger tumorigenesis they constitute rational targets for thera-
peutic interventions.
We demonstrate that the human PTCL-associated fusion 
tyrosine kinase ITK-SYK triggers molecular and cellular fea-
tures of strong TCR signaling in vitro and in vivo. These events 
include tyrosine phosphorylation of TCR-proximal proteins, 
activation of downstream cascades, and functional outcomes 
that, similar to normal antigen receptor signaling, depend on 
the cellular context. Examples are deletion of DP thymocytes 
or activation of T cells in the periphery. Therefore, our re-
sults indicate that ITK-SYK acts as an intracellular mimic of 
a strong antigen receptor signal. Yet ITK-SYK signaling is 
certainly not identical to ligand-induced TCR signaling and 
differs in terms of kinetics and some quantitative aspects like 
induction of maximal IL-2 production. Moreover, normal 
TCR signaling is regularly terminated at the end of an im-
mune response, whereas ITK-SYK signaling is chronic.   
Ultimately,  ITK-SYK  induces  highly  malignant  PTCLs 
with 100% penetrance. The fact that the tumors are clonal 
suggests that cooperating events contribute to proliferative ad-
vantage and outgrowth of individual lymphoma cell clones. 
Notably, sporadic ITK-SYK expression in single T cells of ITK-
SYKCD19-Cre mice drives oncogenesis, indicating that ITK-
SYK is a bona fide oncogene. Secondary oncogenic events 
ITK-SYK expression in single T cells is able to induce T cell 
lymphomas in ITK-SYKCD19-Cre mice
Human cancers do not arise from oncogene expression 
throughout an entire cell lineage but are caused by somatic 
mutations in single tumor cell precursors. Surprisingly, we 
observed that all ITK-SYKCD19-Cre mice eventually also de-
veloped a lethal wasting syndrome (Fig. 8 A) with spleno-
megaly (Fig. 8 B) and infiltration of abnormal lymphocytes 
into multiple organs (Fig. 8, C and D). Although the CD19-
Cre transgene induces very efficient and highly selective ITK-
SYK expression in the B cell lineage (Fig. 2, C and D; and 
Fig. 4), the lymphomas in ITK-SYKCD19-Cre mice were, intrigu-
ingly, all of T cell origin and macroscopically and micro-
scopically indistinguishable from the T cell lymphomas in 
ITK-SYKCD4-Cre mice. They consisted of enlarged, activated, 
and highly proliferative Ki-67+ and TCR-+ ITK-SYK– 
expressing cells (Fig. 8, C–E; and not depicted), which could 
transmit the disease to recipients in transplantation experi-
ments (not depicted). However, in contrast to ITK-SYKCD4-Cre 
mice we never observed mixed CD4+ and CD8+ infiltrates 
in ITK-SYKCD19-Cre mice but, instead, always homogenous 
tumor cell populations that express either CD4, in 75% of 
the cases (Type I), or CD8 (Type II; Fig. 8 F) and which 
were of clonal origin, as determined by surface staining for 
TCR-V chains (Fig. 8 G; n = 12) or Genescan analysis   
(n = 5; not depicted). We therefore conclude that a rare and 
untypical expression of ITK-SYK in the T cell lineage   
of ITK-SYKCD19-Cre mice, presumably as a result of “leaky” 
Cre expression, is able to drive neoplastic transformation 
and malignant expansion of single T cell clones, which 
closely models the pathophysiological situation in human 
PTCL patients.
Figure 7.  Proliferation and infiltration of 
ITK-SYK–expressing T cells upon transplan-
tation. (A) Splenic cells from diseased ITK-
SYKCD4-Cre animals older than 12 wk of age were 
intravenously injected into nude recipient mice 
for transplantation. The frequencies of ITK-SYK–
expressing eGFP+ peripheral blood cells in the 
recipients were monitored over time. Recipients 
that succumbed to the disease are indicated (†). 
Representative examples are shown. 9 out of 10 
donor mice transplanted the disease. Five inde-
pendent transplantations were performed.  
(B) Spleens from a control and a representative 
recipient mouse from A are shown (in centime-
ters). (C) Recipients were sacrificed upon signs of 
disease, and bone marrow (BM) and spleen (SPL) 
suspensions were stained against TCR-. Repre-
sentative frequencies of eGFP fluorescent T cells 
in spleen and bone marrow of 10 analyzed dis-
eased recipients are indicated. (D) Tissue sections 
from spleen (SPL), liver (LIV), and lung (LNG) 
were analyzed after H&E staining or immuno-
histochemistry with anti-CD3 or anti-Ki-67 
antibodies. Bars, 1 mm. Representative examples 
of four analyzed diseased recipients are shown.JEM VOL. 207, May 10, 2010 
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Antigen-mediated TCR ligation induces a recruitment of 
the SYK family member ZAP-70 to the receptor complex for 
LAT and SLP-76 phosphorylation and subsequent cell activation 
(Samelson, 2002). ITK-SYK is constitutively associated with 
lipid rafts and, as such, is presumably in constant proximity to its 
key substrates. The localization of ITK-SYK into the proper   
T cell microdomains is mediated via the PH domain and also 
potentially via the TH domain, which both originate from the 
T cell kinase ITK (Berg et al., 2005). These protein modules are 
known to coordinate membrane localization and binding to 
SLP-76 and LAT in a remarkably selective manner, as ITK does 
not efficiently interact with related B cell molecules including 
might  also  contribute  to  lymphoma  development  in  ITK-
SYKCD19-Cre mice.
Although the ITK-SYK fusion kinase is only found in a 
subset of PTCL patients (Streubel et al., 2006), a recent study 
with >140 PTCL samples reported aberrant expression of acti-
vated SYK in >90% of the cases (Feldman et al., 2008). More-
over, PTCL cells regularly exhibit characteristics of activated   
T cells including their gene expression signatures (Piccaluga 
et al., 2007; Savage, 2007). Together with our experimental 
results, these clinical findings suggest that an aberrant activa-
tion of antigen receptor signaling pathways could be a com-
mon driver of PTCL pathogenesis.
Figure 8.  ITK-SYKCD19-Cre mice develop 
clonal PTCLs. (A) ITK-SYKCD19-Cre mice suc-
cumb to disease. Kaplan-Meier curve of ITK-
SYKCD19-Cre (n = 18) and control (CD19-Cre) 
mice (n = 10). (B) Splenomegaly in ITK-
SYKCD19-Cre mice. Representative spleens 
from 50-wk-old control and ITK-SYKCD19-Cre 
mice are shown (in centimeters). (C) Solid 
organ infiltration with abnormally prolifer-
ating T cells in ITK-SYKCD19-Cre mice. H&E 
staining and immunohistochemistry with 
anti-CD3 and anti–Ki-67 antibodies were 
performed on liver (LIV) and lung (LNG) sec-
tions. Bars, 1 mm. Data representative of six 
diseased ITK-SYKCD19-Cre mice are shown.  
(D) Bone marrow (BM) or spleen (SPL) cell 
suspensions of 50-wk-old control and ITK-
SYKCD19-Cre mice were stained against TCR-. 
The frequency of eGFP+ T cells in a represen-
tative ITK-SYKCD19-Cre mouse is indicated.  
(E) Expanded T cells in ITK-SYKCD19-Cre mice 
display an activated phenotype. CD44 and 
CD62L surface expression on affected T cells 
or controls was assessed using FACS. One 
representative example of CD4+ T cells is 
shown. (F) Spleen cells from diseased ITK-
SYKCD19-Cre mice (n = 16) were stained 
against CD4 and CD8. Examples of preferen-
tial CD4+ T cell (Type I) or CD8+ T cell (Type II) 
expansions are shown. (G) T cell populations 
in ITK-SYKCD19-Cre mice are clonal. Single cell 
suspensions from spleens of individual mice 
were stained with antibodies against CD4, 
CD8, and a panel of antibodies against  
TCR-V chains (see Materials and methods). 
Frequencies of CD4+ or CD8+ cells express-
ing the indicated TCR-V chains in control 
(open histograms) or diseased ITK-SYKCD19-Cre 
(gray histograms) mice are shown. Data in  
B and D–G are representative of six inde-
pendent experiments with a total number of 
at least 10 mice analyzed per genotype are 
shown. If not indicated otherwise, all panels 
show data from ITK-SYKCD19-Cre mice  
that were older than 40 wk and showed 
disease symptoms.1042 New model of peripheral T cell lymphoma | Pechloff et al.
using standard molecular biology techniques as previously described (Grundler   
et al., 2005). Retroviral particles were generated upon transfection of Phoenix-E 
packaging cells as previously described (Grundler et al., 2005).
Cell culture. Jurkat cells were cultured in RPMI-1640 medium supple-
mented with 10% fetal bovine serum. Phoenix-E packaging cells were main-
tained in DME supplemented with 10% fetal bovine serum. The SYK 
inhibitor R406 (Rigel Pharmaceuticals) was used at a final concentration of 
2 µM where indicated.
ELISA. Cell supernatants from Jurkat cells were harvested 36 h after retro-
viral infection and CD3 (10 µg/ml)/CD28 (2 µg/ml) stimulation as indi-
cated. IL-2 concentrations were determined via ELISA (OptEIA Human 
IL-2 ELISA Set; BD).
T and B cell purification. For protein analysis, T or B cells from spleen 
or lymph nodes were isolated by negative selection with magnetic beads 
(Dynabeads; Invitrogen) and antibodies against CD11b, B220, or Thy1.2 as 
previously described (Ferch et al., 2007).
Lipid raft preparation. 107 Jurkat cells or 5 × 107 purified lymphocytes per 
assay point were kept unstimulated or stimulated with 5 µg/ml CD3/1 µg/ml 
CD28 for 5 min as indicated and subsequently lysed in Brij lysis buffer as pre-
viously described (Ferch et al., 2007). Mice older than 12 wk were used for T cell 
preparations to obtain sufficient numbers of ITK-SYK–expressing T lympho-
cytes. Postnuclear supernatants were mixed with 85% (wt/vol) sucrose, 
overlaid with 35% (wt/vol) and 5% (wt/vol) sucrose, and separated by ultra-
centrifugation. Lipid raft and cytoplasmatic fractions were analyzed for the 
presence of the lipid raft marker GM1 (Ferch et al., 2007).
Western blot analysis. For whole cell protein analysis, Jurkat cells or 
primary lymphocytes were lysed with CHAPS buffer and subsequently 
subjected to Western blot analysis as previously described (Ferch et al., 
2007). Alternatively, lipid raft or nonraft fractions were analyzed. The following 
antibodies were used: anti-Emt (2F12; mouse monoclonal; Santa Cruz Biotech-
nology, Inc.) for ITK or ITK-SYK detection, anti–phospho-tyrosine (P-Tyr-100; 
mouse monoclonal; Cell Signaling Technology), anti–phospho-PLC1 
(Tyr783; rabbit polyclonal; Cell Signaling Technology), and anti--actin 
(20–33; Sigma-Aldrich).
Flow cytometry. FACS analysis was performed using standard protocols 
(Ferch et al., 2007). In brief, Jurkat cells were either surface stained with 
anti-human CD69 antibody or intracellularly stained after permeabilization 
with 70% ice-cold methanol with antibodies against phosphorylated forms   
of SLP-76 (pY128), LAT (pY171), PLC1 (pY783), AKT (pS473), ERK1/2 
(pT202/pY204), or p38 (pT180/pY182). Primary cell suspensions from thy-
mus, spleen, lymph nodes, bone marrow, or peripheral blood were directly 
labeled. Single cell suspensions from liver, kidney, or lung were first purified 
by Percoll gradient centrifugation. Fluorescently labeled antibodies against 
the  following  surface  proteins  were  used  for  mouse  cell  staining:  B220 
(RA3_6B2); TCR- (H57-597); CD3 (1452C11); CD4 (Gk1.5); CD5 
(53–7.3); CD8 (53–6.7); CD21/35 (7G6); CD23 (B3B4); CD44 (IM7); 
CD62L (MEK-14); CD86 (GL1); IgM (II/41), V3-TCR (KJ25), V4-
TCR (CTVB4), V6-TCR (RR4-7), V7-TCR (TR310), V8.1/8.2-
TCR  (MR5-2),  V8.3-TCR  (CT-8C1),  V10b-TCR  (CTVB10b), 
V11-TCR (CTVB11), and V12b-TCR (CTVB12b). Data were acquired 
on a FACSCalibur or FACSCanto II flow cytometer (BD). FlowJo Software 
(Tree Star, Inc.) was used for data analysis.
Histology. All organs were fixed in 4% formaldehyde and paraffin embed-
ded. 3–5-µm-thick sections were cut and stained with H&E. Immunohisto-
chemistry was performed on an automated immunostainer (Ventana Medical 
Systems, Inc.) according to the company’s protocols for open procedures 
with slight modifications. The antibody panel used included CD3 (SP7; 
Thermo Fisher Scientific), B220 (BD), Ki-67 (SP6; Thermo Fisher Scientific), 
SLP-65 (Hashimoto et al., 1999; Su et al., 1999; Bunnell   
et al., 2000). This might explain why B cell–intrinsic expression 
of ITK-SYK has no apparent effects in the B cell lineage. Con-
sistent with our findings, ITK-SYK kinase activity and mem-
brane localization are also required for ITK-SYK–mediated 
transformation of an immortalized fibroblast cell line in vitro 
(Rigby et al., 2009). Together, these results suggest that thera-
peutic strategies for ITK-SYK inhibition could either target the 
ITK-SYK kinase activity or try to interfere with ITK-SYK lo-
calization. Our experiments in Jurkat cells demonstrated that 
the SYK kinase inhibitor R406 can very potently block ITK-
SYK signaling. Still, it is currently unclear whether constitutive 
ITK-SYK signaling is predominantly responsible for tumor   
initiation or also essential for disease maintenance. Thus, studies 
are necessary that investigate the responsiveness of ITK-SYK–
induced lymphoma to R406 treatment in vivo.
Aberrant antigen receptor signaling is frequently observed 
in human lymphoid malignancies beyond PTCL. Chronic 
active BCR signaling was recently described in diffuse large 
B cell lymphomas (Davis et al., 2010). Other lymphoma enti-
ties with aberrant activities of antigen receptor signaling path-
ways  are  chronic  lymphocytic  leukemias,  which  regularly 
show aberrant ZAP-70 expression, mucosa-associated lym-
phoid tissue lymphomas, which often develop in the context 
of chronic antigenic stimulation, or follicular lymphoma 
(Küppers, 2005). Our study provides in vivo evidence that 
constitutively enforced antigen receptor signals are directly 
able to induce oncogenesis. The downstream signaling cas-
cades that are critical for lymphoma initiation or maintenance 
are not well defined. The presented mouse models will serve 
as valuable tools to genetically dissect these pathways in vivo. 
Finally, in addition to the mentioned SYK inhibitor, several 
small molecule drugs, which interfere with antigen receptor 
signaling, are already available or are in preclinical or clinical 
development for malignant or nonmalignant immune-mediated 
diseases. Our clinically relevant PTCL model will help to 
identify compounds that could be of potential use for the 
treatment of PTCLs. In light of the minimal effectiveness of 
conventional chemotherapy in PTCL treatment such studies are 
urgently warranted.
MATERIALS AND METHODS
Animals. Human ITK-SYK cDNA (Streubel et al., 2006) was cloned into 
a Rosa26 targeting vector (Sasaki et al., 2006), linearized, and electroporated 
into E14K embryonic stem cells as previously described (Ruland et al., 2001). 
Successful homologous recombination at the Rosa26 locus was confirmed 
by standard Southern blot analysis using a 5 flanking probe as previously   
described (Ruland et al., 2001). Blastocyst injection of two independent 
clones and subsequent chimera breeding resulted in Rosa26loxSTOPlox-ITK-SYK 
mice. Rosa26loxSTOPlox-ITK-SYK mice were crossed with either CD4-Cre (Lee 
et al., 2001) or CD19-Cre mice (Rickert et al., 1997). Littermates were used 
in all subsequent experiments. Athymic Foxn1nu/nu mice purchased from 
Harlan were used as recipients in transplantation experiments. Studies were 
conducted according to federal and institutional guidelines. Animal proto-
cols were approved by the government of Upper Bavaria.
Retroviral expression vectors. Retroviral constructs were generated by 
cloning ITK-SYK, ITK-SYK (K262R) (ITK-SYKKD), or ITK-SYK (R29C) 
(ITK-SYKPHmut) cDNA into IRES GFP containing MSCV-based vectors JEM VOL. 207, May 10, 2010 
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and cleaved Caspase 3 (ASP 175; Cell Signaling Technology). Appropriate 
positive controls were used to confirm the adequacy of the staining.
Genescan analysis. Genomic DNA was extracted from total splenic cell 
suspensions of diseased ITK-SYKCD4-Cre, ITK-SYKCD19-Cre, or control mice 
(CD4-Cre or CD19-Cre, respectively). V-D-J and incomplete D-J re-
arrangements of the TCR- locus were analyzed via five individual PCR   
reactions with the following primer combinations: V(1–20)-J1, V(1–20)-
J2, D1-J1, D2-J2, and D1-J2. Primer sets consisted of a mixture 
of 20 family-specific upstream primers located within the V gene seg-
ments or consensus primers immediately located 5 of the D1/D2 re-
arrangement and 5FAM-labeled consensus primers immediately located 3 
of the J1/J2 rearrangement as previously described (Gärtner et al., 1999). 
TCR- locus rearrangement was analyzed with a PCR reaction using a V4 
and a 5-FAM–labeled J1 consensus primer as described (Kawamoto et al., 
2000). 5-FAM–labeled PCR products were size separated by capillary 
POP-7-Polymer electrophoresis and visualized via automated scanning by 
using a 3700 Genetic Analyzer (Applied Biosystems). Reagents were all ob-
tained from Applied Biosystems. Fragment size distribution was determined 
by GeneMapper software (Applied Biosystems) and analyzed as previously 
described (Kneba et al., 1995; van Dongen et al., 2003).
Transplantation. 6-wk-old athymic Foxn1nu/nu mice (Harlan) were intra-
venously injected with 1.5 × 107 splenocytes isolated from diseased ITK-
SYKCD4-Cre or ITK-SYKCD19-Cre mice. Recipients were monitored daily for 
signs of disease and blood samples were analyzed by FACS at the indicated 
time points.
Statistical analysis. Where indicated, results were analyzed for statistical 
significance with the unpaired two-tailed Student’s t test. Differences   
between groups were considered as significant at p-values <0.05.
Online supplemental material. Fig. S1 shows results from phosflow experi-
ments investigating the phosphorylation status of TCR signaling molecules 
upon CD3/CD28 stimulation in retrovirally infected Jurkat cells. Fig. S2 
presents the immunohistochemical expression analysis of CD3, Ki-67, and the 
active form of Caspase 3 (Caspase 3A) in spleen sections from of 4–5-wk-old 
ITK-SYKCD4-Cre or control CD4-Cre animals. Online supplemental material 
is available at http://www.jem.org/cgi/content/full/jem.20092042/DC1.
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